Get the Stockscreener App
207.63
1.12%
-2.63
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $207.63, with a volume of 744.03K.
It is down -1.12% in the last 24 hours and down -5.36% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$210.26
Open:
$208.99
24h Volume:
744.03K
Relative Volume:
0.10
Market Cap:
$367.20B
Revenue:
$61.16B
Net Income/Loss:
$4.19B
P/E Ratio:
87.93
EPS:
2.3614
Net Cash Flow:
$17.82B
1W Performance:
-1.74%
1M Performance:
-5.36%
6M Performance:
-8.10%
1Y Performance:
+17.59%
1-Day Range:
$207.38
$209.82
1-Week Range:
$203.01
$214.10
52-Week Range:
$168.54
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
207.60 | 371.90B | 61.16B | 4.19B | 17.82B | 2.3614 |
LLY
Lilly Eli Co
|
924.23 | 824.12B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
239.15 | 578.31B | 94.19B | 26.80B | 19.70B | 11.05 |
AZN
Astrazeneca Plc
|
202.30 | 316.96B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
118.69 | 296.29B | 64.93B | 18.26B | 12.36B | 7.2751 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
NSCLC Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | AbbVie, AstraZeneca and Daiichi Sankyo, Shanghai Henlius Biotech, Moderna Therapeutics/ Merck, BeyondSpring, Cullinan - Barchart
RemeGen (09995.HK) Receives USD650M Upfront Payment from AbbVie for RC148 - AASTOCKS.com
AbbVie (ABBV) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance Singapore
AbbVie Inc. stock (US00287Y1091): Is its immunology dominance strong enough to unlock new upside? - AD HOC NEWS
BRAF Mutated Non-small Cell Lung Cancer Market: Rapid Increment Driven by Innovation by 2036 – DelveInsight | AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics - Barchart.com
Abbvie nabs two Nav1.8 pain projects from Haisco in $745M deal - BioWorld News
Could AbbVie Crash Lilly's Weight‑Loss Party? - The Globe and Mail
AbbVie Inc. stock (US00287Y1091): Is immunology dominance strong enough to unlock new upside? - AD HOC NEWS
ABBV stock shows mixed momentum on neutral MACD reading: weekly review - Traders Union
Natural Investments Trims Stake in AbbVie - National Today
JM2 Capital Inc. Buys Shares of 2,519 AbbVie Inc. - National Today
Erin Lichy Gets Real About Her Natrelle® Breast Augmentation - AbbVie News Center
Erin Lichy shares her breast augmentation story in Natrelle campaign - Stock Titan
Haisco Pharma strikes deal with AbbVie to develop novel pain medicines - The Pharma Letter
AbbVie Ovarian Cancer Data And Pain Deal Extend Long Term Story - Yahoo Finance
What is behind AbbVie stock's recent drop in value today - Traders Union
AbbVie’s Elahere succeeds in Phase II platinum-sensitive ovarian cancer trial - Yahoo
Eli Lilly's Jaypirca Builds Case With Fourth Positive Phase 3 Trial In Blood Cancer Patients - Benzinga
Haisco Grants AbbVie Exclusive Rights to Advance Novel Pain Medicines - Contract Pharma
Abbvie licenses ex-China rights to Haisco pain compounds - BioWorld News
Will AbbVie's Neuroscience Franchise Aid Top-line Growth in Q1? - TradingView — Track All Markets
AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid - Pharmaceutical Technology
AbbVie (ABBV) Ends Development Agreement, CollPlant Eyes New Opp - GuruFocus
CollPlant announces termination of development agreement with AbbVie - TipRanks
CollPlant ends AbbVie deal, cuts workforce by 50% - Investing.com Canada
AbbVie ends CollPlant (NASDAQ: CLGN) filler pact as CollPlant slashes workforce 50% - Stock Titan
DB&C Advisors, LLC's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie (ABBV) Partners with Haisco for Pain Therapy Development - GuruFocus
Haisco Pharmaceutical Group Co., Ltd. Enters Exclusive License Agreement with AbbVie - marketscreener.com
AbbVie, Inc. Trade Ideas — BSESOF:4AB - TradingView — Track All Markets
Haisco licenses pain drug candidates to AbbVie for $745 million By Investing.com - Investing.com Canada
Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain - Yahoo Finance
AbbVie Inc. (ABBV): A Bull Case Theory - MSN
AbbVie (ABBV) to Present Promising Trial Results at SGO Annual M - GuruFocus
AbbVie stock falls 2.05% as new ovarian cancer data shared at SGO meeting - Traders Union
Sumitomo Mitsui Trust Group Trims AbbVie Stake - National Today
AbbVie Showcases Late?Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx in Platinum?Sensitive Ovarian Cancer at SGO 2026 - Investing News Network
Significant BD revenue contribution: Hisun Q1 net profit forecast increases up to nearly 11 times. Another major BD deal worth $745 million signed with AbbVie. - 富途牛牛
AbbVie ovarian cancer drug shows 62.7% response rate in trial - Investing.com
Haisco Pharmaceutical Signs Licensing Agreement With AbbVie Group - TradingView — Track All Markets
AbbVie's ELAHERE Demonstrates Unexpected PSOC Effectiveness, Boosting Anticipated Expansion - Bitget
AbbVie stock price forecast: sellers in control as ABBV fails to hold above support - Traders Union
Massachusetts Financial Firm Trims Stake in AbbVie - National Today
-2.05% for AbbVie stock as renewed selling keeps shares below key resistance - Traders Union
Factory Mutual Insurance Co. Decreases AbbVie Stock Position - National Today
AbbVie (ABBV) Receives a Buy from RBC Capital - The Globe and Mail
INVESCO Health Care Fund's AbbVie Inc(ABBV) Holding History - GuruFocus
CapEx per share of AbbVie, Inc. – BSESOF:4AB - TradingView — Track All Markets
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
Sector Update: Health Care - Moomoo
MML Fundamental Value Fund's AbbVie Inc(ABBV) Holding History - GuruFocus
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):